Anti-FMC7 Ag. Antibody, FITC

This product recognizes a glycoprotein antigen of 105kD expressed by B lymphocytes. The FMC7 antigen is expressed by peripheral B lymphocytes, and has been used widely in the study of B cell malignancy. FMC7 has been used extensively to differentiate various types of B cell malignancy. B-CLL is generally considered to be negative for FMC7 expression, but strong staining is seen in many other types of B cell lymphoma, including prolymphocytic leukaemia and hairy cell leukaemia.

The nature of the FMC7 antigen has remained poorly defined following its first description in 1981. The expression pattern closely corresponds to that seen with CD22, but studies have shown that FMC7 does not recognize the CD22 molecule itself. A recent publication by Serke et al. has shown that FMC7 recognizes a conformational epitope on the CD20 molecule, most likely a multimeric complex of CD20.

FMC7 Ag.